Type 2 diabetes is one of the most actively researched conditions in the US, with hundreds of clinical trials enrolling participants at any given time. The development of GLP-1 receptor agonists, SGLT-2 inhibitors, and emerging dual and triple agonists has produced a robust pipeline of investigational therapies, with another wave of novel mechanisms in earlier development. For patients with type 2 diabetes, clinical trials for type 2 diabetes offer access to advanced therapies before approval, potential reduction in medication costs during participation, and intensive monitoring of glucose control. This guide covers how to find diabetes trials, the categories of treatments being tested, typical eligibility criteria, and what to expect from enrollment.
Categories of type 2 diabetes trials
Active type 2 diabetes trials in 2026 fall into several categories:
Next-generation GLP-1 and incretin therapies: Once-weekly and once-monthly GLP-1 agonists, oral semaglutide, dual GLP-1/GIP agonists (similar to tirzepatide), and triple agonists (GLP-1/GIP/glucagon) targeting glucose control and weight loss simultaneously.
SGLT-2 inhibitor combinations: Combination products with metformin, GLP-1s, or other classes; new SGLT-2 mechanisms; and trials testing SGLT-2s in expanded indications (heart failure, chronic kidney disease).
Insulin innovations: Once-weekly basal insulins, “smart” insulins that respond to glucose levels, and ultra-rapid prandial insulins.
Beta-cell preservation and regeneration: Therapies aimed at protecting or regenerating insulin-producing beta cells, potentially reversing rather than just managing diabetes.
Novel mechanisms: Glucokinase activators, FGF21 analogs, mitochondrial uncouplers, and other approaches targeting different aspects of metabolic dysfunction.
Lifestyle and digital therapeutics: App-based behavioral interventions, continuous glucose monitor-guided lifestyle programs, and structured weight loss programs.
Where to find type 2 diabetes trials
The primary search resources:
- ClinicalTrials.gov — federal database with thousands of active type 2 diabetes trials searchable by location and phase
- American Diabetes Association — maintains research and trial information
- JDRF — primarily type 1 diabetes but some type 2 research
- Major academic medical centers (Joslin Diabetes Center, Yale, UCSF, Vanderbilt, etc.)
- ResearchMatch for matching with active studies
Pharmaceutical company-sponsored trials for major drugs typically run at hundreds of sites across the US. For a starting point on broader trial searching, see our how to find clinical trials guide.
Typical eligibility criteria for type 2 diabetes trials
Common inclusion criteria:
- Adults 18-75 (sometimes 18-65 or 18-80)
- Confirmed type 2 diabetes diagnosis (typically requiring documentation of duration and prior treatment)
- A1c in a specific range — often 7.0-10.0% or 7.0-11.0%, depending on the trial’s target patient population
- Stable diabetes medications for a period (often 8-12 weeks before screening)
- BMI typically in a specific range (often 25-45)
- Adequate kidney and liver function
Common exclusion criteria:
- Type 1 diabetes
- Recent heart attack, stroke, or other major cardiovascular event
- Severe kidney disease (eGFR below 30 typically)
- Pregnancy or planned pregnancy
- Active cancer
- History of pancreatitis (for trials of GLP-1s and similar mechanisms)
- Personal or family history of medullary thyroid carcinoma (for GLP-1 trials, per FDA labeling)
- Recent participation in other interventional trials
What participation typically involves
Most type 2 diabetes trials involve:
- Initial screening visit with detailed medical history, physical exam, lab work, and ECG
- Randomization (in randomized trials) to either the experimental treatment or placebo/active comparator
- Regular study visits typically every 4-12 weeks during active treatment
- A1c measurements at each visit
- Continuous glucose monitoring in some trials
- Weight, blood pressure, and other vital signs monitoring
- Lipid panels and other metabolic labs
- Patient-reported outcomes via questionnaires
- Follow-up visits after the active treatment period ends
Total trial duration ranges from 12 weeks (small Phase 2 studies) to 5+ years (cardiovascular outcome trials testing whether the drug reduces heart attacks and strokes).
What participants gain
Type 2 diabetes trial participation can offer:
- Access to potentially advanced therapies before they’re approved
- Intensive monitoring of glucose control with frequent A1c checks
- Free study medication during the trial
- Continuous glucose monitor access in many trials
- Education and support beyond what most insurance covers
- Compensation for time and travel ($25-100 per visit typically)
- Contribution to research that could benefit other patients
For patients struggling with glucose control on standard medications, trials may offer therapies that work better than current options. The intensive monitoring also catches issues earlier than standard care.
What participants should consider
Trial participation isn’t for everyone. Considerations:
- The placebo possibility — some trials randomize to placebo, meaning you may not receive the experimental drug
- Time commitment — visits can require travel, time off work, and sustained engagement over months or years
- Restrictions on medication changes — most trials require you to stay on study medications and avoid changes during the trial
- Potential side effects — experimental drugs may have unknown adverse effects
- Insurance and standard care continuation — your standard medical care continues but may be affected by trial participation
Discuss with your endocrinologist or primary care physician before enrolling. They can put the trial in context with your specific situation and help evaluate whether participation makes sense.
Active treatment areas and notable mechanisms
The most active areas of type 2 diabetes drug development in 2026:
Triple agonists (GLP-1/GIP/glucagon): Drugs that activate three metabolic hormone receptors simultaneously. Early data suggests potentially superior glucose and weight effects compared to current dual agonists. Multiple Phase 2 and 3 trials are active.
Oral GLP-1s: Pill formulations of semaglutide and other GLP-1s, with trials testing whether oral delivery can match injectable efficacy at doses tolerable for chronic use.
Glucokinase activators: Drugs that activate glucokinase, the enzyme that senses glucose and triggers insulin release. The class has had mixed history but newer molecules are in development.
Beta-cell preservation: Various approaches aimed at preserving or restoring beta-cell function, potentially modifying the underlying disease rather than just managing symptoms.
Frequently Asked Questions
Are type 2 diabetes trials only for newly diagnosed patients?
No. Trials enroll across the full spectrum — newly diagnosed, those on metformin, those on multiple medications, those on insulin. Different trials target different patient populations.
Will I get GLP-1 medication through a trial?
Possibly, depending on the trial. Many active trials include GLP-1s, dual agonists, or triple agonists. In randomized placebo-controlled trials, you have a chance of receiving placebo. Trials comparing experimental drugs to active comparators may give you a different active drug rather than placebo.
Can I continue my current diabetes medications?
Depends on the trial. Some trials require you to stop specific medications and start the experimental treatment alone; others allow continuation of background medications. The protocol determines what’s allowed.
How long do type 2 diabetes trials last?
Phase 2 trials are often 12-26 weeks. Phase 3 trials are often 26-52 weeks. Cardiovascular outcome trials can run 3-5+ years to detect rare cardiovascular events.
Will trial participation help my A1c?
Possibly, if you receive the experimental treatment and it’s effective. The intensive monitoring alone often improves A1c in many participants regardless of treatment assignment.
The bottom line on type 2 diabetes trials
Type 2 diabetes is among the most actively researched conditions, with hundreds of trials testing GLP-1 advances, novel mechanisms, beta-cell preservation, and digital therapeutics. Enrollment is straightforward through ClinicalTrials.gov and academic medical center programs. For patients struggling with glucose control on standard medications, trials offer access to potentially advanced therapies plus intensive monitoring. The placebo possibility and time commitment are real considerations. Discuss with your endocrinologist and consider trials as one option in a comprehensive diabetes management plan.